Latest news and press releases about Eli Lilly and Company (LLY): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500).
Price
| Price | $1,143.12 |
| Market Cap | $1.1T |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| P/E Ratio | 38.35 |
| Price / Book | 30.10 |
| EV / EBITDA | 25.92 |
| Dividend Yield | 0.59% |
Profitability
| Return on Equity | 92.58% |
| Return on Invested Capital | 31.00% |
| Return on Assets | 18.77% |
| Gross Margin | 83.40% |
| Operating Margin | 49.72% |
| Net Margin | 33.53% |
Related companies: ABBV · AMGN · AZN · GILD · JNJ · MRK · NVO
Explore sector: Healthcare · Drug Manufacturers - General
More sections of LLY: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks